Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-04-05 @ 10:09 PM
Study NCT ID:
NCT07406035
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-12
First Post:
2026-01-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2026-03-25'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015535', 'term': 'Arthritis, Psoriatic'}], 'ancestors': [{'id': 'D025242', 'term': 'Spondylarthropathies'}, {'id': 'D025241', 'term': 'Spondylarthritis'}, {'id': 'D013166', 'term': 'Spondylitis'}, {'id': 'D013122', 'term': 'Spinal Diseases'}, {'id': 'D001847', 'term': 'Bone Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D011565', 'term': 'Psoriasis'}, {'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C479163', 'term': 'tofacitinib'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 156}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2026-04', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2027-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2026-02-05', 'studyFirstSubmitDate': '2026-01-29', 'studyFirstSubmitQcDate': '2026-02-05', 'lastUpdatePostDateStruct': {'date': '2026-02-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2026-02-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'American College of Rheumatology 20% Improvement Criteria', 'timeFrame': 'Day 1, 15, 29, 57, 85', 'description': 'The proportion of trial participants achieving an ACR20 response at Week 12.'}], 'secondaryOutcomes': [{'measure': 'ACR20 in the subgroup of trial participants', 'timeFrame': 'Day 1, 15, 29, 57, 85', 'description': 'The proportion of biologic-naive trial participants in the subgroup who achieved ACR20 response at Week 12.'}, {'measure': 'American College of Rheumatology 50 (ACR50)', 'timeFrame': 'Day 1, 15, 29, 57, 85', 'description': 'ACR50 response rate'}, {'measure': 'American College of Rheumatology 70 (ACR70)', 'timeFrame': 'Day 1, 15, 29, 57, 85', 'description': 'ACR70 response rate'}, {'measure': 'Psoriasis Area and Severity Index (PASI) 75', 'timeFrame': 'Day 1, 15, 29, 57, 85', 'description': 'PASI 75 response rate'}, {'measure': 'Psoriasis Area and Severity Index 90', 'timeFrame': 'Day 1, 15, 29, 57, 85', 'description': 'PASI 90 response rate'}, {'measure': 'Numbers of subjects with incidence of adverse Event (AE), serious Adverse Event (SAE), adverse event leading to study discontinuation, adverse event of special interest (AESI)', 'timeFrame': 'From the time trial participants sign the informed consent form to 28 days after the last dose', 'description': 'Numbers of subjects with incidence rates of Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events Leading to Study Discontinuation, and Adverse Events of Special Interest (AESIs)'}, {'measure': 'Time to Peak Concentration (Tmax)', 'timeFrame': 'Up to day 85', 'description': 'Evaluation of the Time to Peak Concentration (Tmax) of TQH3906 in participants with Psoriatic Arthritis after oral administration.'}, {'measure': 'Peak Concentration (Cmax)', 'timeFrame': 'Up to day 85', 'description': 'Evaluation of the Peak Concentration (Cmax) of TQH3906 in Participants with Psoriatic Arthritis After Oral Administration'}, {'measure': 'Plasma Clearance (CL/F)', 'timeFrame': 'Up to day 85', 'description': 'Evaluation of the Plasma Clearance (CL/F) of TQH3906 in Participants with Psoriatic Arthritis After Oral Administration.'}, {'measure': 'Plasma Elimination Half-Life (t₁/₂)', 'timeFrame': 'Up to day 85', 'description': 'Evaluation of the Plasma Elimination Half-Life (t₁/₂) of TQH3906 in Participants with Psoriatic Arthritis After Oral Administration.'}, {'measure': 'Trough Concentration at Steady State (Cmin, ss)', 'timeFrame': 'Up to day 85', 'description': 'Evaluation of the Trough Concentration at Steady State (Cmin, ss) of TQH3906 in Participants with Psoriatic Arthritis After Oral Administration.'}, {'measure': 'Degree of Fluctuation (DF)', 'timeFrame': 'Up to day 85', 'description': 'Evaluation of the Degree of Fluctuation (DF) of TQH3906 in Participants with Psoriatic Arthritis After Oral Administration.'}, {'measure': 'Evaluation of Interleukin (IL) Levels in Participants with Psoriatic Arthritis Treated with TQH3906', 'timeFrame': 'Blood samples were collected within 1 hour before dosing at Baseline, Weeks 2, 4, 8, and 12', 'description': 'Evaluation of Interleukin (IL) Levels in Participants with Psoriatic Arthritis Treated with TQH3906'}, {'measure': 'Evaluation of Defensin Levels in Participants with Psoriatic Arthritis Treated with TQH3906', 'timeFrame': 'Blood samples were collected within 1 hour before dosing at Baseline, Weeks 2, 4, 8, and 12', 'description': 'Evaluation of Defensin Levels in Participants with Psoriatic Arthritis Treated with TQH3906'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Psoriatic Arthritis']}, 'descriptionModule': {'briefSummary': 'This study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active Psoriatic Arthritis (PsA) at Week 12, with the proportion of participants achieving an American College of Rheumatology 20% (ACR20) Improvement Criteria (ACR20) response at Week 12 as the primary endpoint.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Sign a written Informed Consent Form, which must meet the following requirements\n\n * Be willing to participate in the study and able to sign the informed consent form;\n * Be willing and able to complete all study-specific procedures and visits;\n* PsA trial participant disease characteristics\n\n * Aged 18 to 70 years（inclusive）;\n * BMI ≥ 18 kg/m² at screening; diagnosed with PsA for at least 3 months prior to screening, and meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening;\n * Active arthritis at screening and at baseline (Day 1);\n * Has failed or was intolerant to at least one prior therapy;\n * If receiving a conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD), trial participants must be on only one DMARD, which must have been administered for at least 3 months prior to screening, with a stable dose for at least 28 days prior to the first dose;\n * If using NSAIDs, the dose must have been stable for at least 14 days before the first dose;\n * If using oral corticosteroids, the dose must have been stable for at least 14 days before the first dose;\n * Topical treatments for plaque psoriasis must have remained stable for at least 14 days before the first dose;\n* Women of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of the study; men must agree to use effective contraception during the study and for 6 months after the end of the study\n\nExclusion Criteria:\n\n* Presence of conditions other than PsA:\n\n * Presence of non-plaque psoriasis (i.e., guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) at screening or first dose;\n * Presence of any other autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, etc.;\n * Presence of active (i.e., currently symptomatic) fibromyalgia;\n* Other Medical Conditions and Medical History:\n\n * Trial participants who are pregnant or breastfeeding;\n * Evidence of a serious illness/condition or unstable clinical condition, or localized active infection/infectious disease;\n * Any major surgery performed within 30 days prior to the first dose of study treatment, or any planned surgery during the study;\n * Cancer or a history of cancer or lymphoproliferative disease within the past 5 years;\n * New York Heart Association (NYHA) Class III or IV congestive heart failure, or any recent episode of heart failure resulting in NYHA Class III/IV symptoms; or a history of clinically significant ventricular arrhythmia or arrhythmia requiring continuous antiarrhythmic drug therapy;\n * Uncontrolled hypertension at screening or randomization;\n * History of thrombotic disease within 24 weeks prior to screening; viii. History of acute coronary syndrome and/or any major cerebrovascular disease within 24 weeks prior to screening;\n * Current or recent (within 3 months prior to randomization) gastrointestinal disease that may affect absorption of study treatment, including gastrointestinal surgery;\n * Severe blood loss (\\> 500 mL) or blood transfusion within 4 weeks prior to randomization;\n * Inability to take oral medication;\n * Inability to undergo venipuncture and/or tolerate venous access;\n * History of substance abuse with inability to abstain or presence of a psychiatric disorder;\n * Any other medical, psychiatric, and/or social reason as determined by medical judgment;\n* Prior and concomitant medications: If the trial participant has a history of biologic use, the exclusion criteria specified in the protocol will apply;\n* Infection-related:\n\n * Active tuberculosis identified by chest radiography within 6 months prior to screening; trial participants with a negative chest radiography within 3 months prior to screening are eligible if they meet the protocol requirements;\n * Hepatitis C, hepatitis B, or human immunodeficiency virus (HIV) infection; or syphilis infection requiring treatment;\n* Abnormal physical examination or laboratory findings;\n* Other:\n\n * History of any major drug allergy; known allergy to any excipient of the investigational product;\n * Inability to comply with the trial protocol;\n * History of substance abuse with inability to abstain or presence of a psychiatric disorder;\n * Participation in another clinical trial and use of another investigational drug (other than for psoriatic arthritis) within 4 weeks prior to the first dose, based on the date of discontinuation from the previous trial;\n * Planned or previous allogeneic bone marrow transplantation or solid organ transplantation;\n * Any condition that, in the investigator's judgment, poses a serious risk to the safety of the trial participant or affects the participant's ability to complete the study."}, 'identificationModule': {'nctId': 'NCT07406035', 'briefTitle': 'A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'}, 'officialTitle': 'A Randomized, Placebo- and Active Drug-Controlled, Double-Blind, Multicenter, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis', 'orgStudyIdInfo': {'id': 'TQH3906-II-02'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'TQH3906 Capsule 24 mg', 'description': 'Oral administration daily from Day 1 (D1) to Day 85 (D85) Morning Fasting: 3 Capsules of 8 mg TQH3906', 'interventionNames': ['Drug: TQH3906 Capsule']}, {'type': 'EXPERIMENTAL', 'label': 'TQH3906 Capsule 16 mg', 'description': 'Oral administration daily from Day 1 (D1) to Day 85 (D85) Morning fasting: 2 capsules of 8 mg TQH3906', 'interventionNames': ['Drug: TQH3906 Capsule']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'TQH3906 Capsule 0 mg', 'description': 'Oral administration daily from Day 1 (D1) to Day 85 (D85) Morning fasting: 3 placebo capsules of TQH3906', 'interventionNames': ['Drug: TQH3906 Placebo Capsule']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Tofacitinib Citrate Tablet 5 mg', 'description': 'Oral administration daily from Day 1 (D1) to Day 85 (D85):\n\nMorning fasting: 1 tablet of tofacitinib citrate Administer 1 tablet of Tofacitinib Citrate at bedtime.', 'interventionNames': ['Drug: Tofacitinib Citrate Tablet 5 mg']}], 'interventions': [{'name': 'TQH3906 Capsule', 'type': 'DRUG', 'description': 'TQH3906 is a small-molecule inhibitor of tyrosine kinase.', 'armGroupLabels': ['TQH3906 Capsule 16 mg', 'TQH3906 Capsule 24 mg']}, {'name': 'TQH3906 Placebo Capsule', 'type': 'DRUG', 'description': 'Placebo without drug substance.', 'armGroupLabels': ['TQH3906 Capsule 0 mg']}, {'name': 'Tofacitinib Citrate Tablet 5 mg', 'type': 'DRUG', 'description': 'Tofacitinib Citrate Tablets are Janus kinase (JAK) inhibitors.', 'armGroupLabels': ['Tofacitinib Citrate Tablet 5 mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '236805', 'city': 'Bozhou', 'state': 'Anhui', 'country': 'China', 'contacts': [{'name': 'Yuhui Zhang, Doctor', 'role': 'CONTACT', 'email': 'clearhui1118@126.com', 'phone': '18905688161'}], 'facility': "Bozhou People's Hospital", 'geoPoint': {'lat': 33.87722, 'lon': 115.77028}}, {'zip': '100000', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Peking Union Medical College Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '400038', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'country': 'China', 'contacts': [{'name': 'Bing Zhong, Master', 'role': 'CONTACT', 'email': 'dune_zhong@163.com,', 'phone': '18203063388'}], 'facility': 'Southwest Hospital, Third Military Medical University (Army Medical University)', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '523109', 'city': 'Dongguan', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Guangming Han, Doctor', 'role': 'CONTACT', 'email': 'ghan54321@163.com', 'phone': '13533391069'}], 'facility': "Dongguan People's Hospital", 'geoPoint': {'lat': 23.01797, 'lon': 113.74866}}, {'zip': '510400', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Changsong Lin, Master', 'role': 'CONTACT', 'email': '13802772276@163.com', 'phone': '13802772276'}], 'facility': 'The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510630', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Yunfeng Pan, Doctor', 'role': 'CONTACT', 'email': 'panyunfeng@medmail.com.cn', 'phone': '18922102921'}], 'facility': 'The Third Affiliated Hospital of Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '529030', 'city': 'Jiangmen', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Chujun Ouyang, Doctor', 'role': 'CONTACT', 'email': 'chelly1122@126.com', 'phone': '13630480333'}], 'facility': 'Jiangmen Central Hospital', 'geoPoint': {'lat': 22.58333, 'lon': 113.08333}}, {'zip': '518035', 'city': 'Shenzhen', 'state': 'Guangdong', 'country': 'China', 'contacts': [{'name': 'Meiying Wang, Doctor', 'role': 'CONTACT', 'email': 'wmy99wmy99@163.com', 'phone': '13723769919'}], 'facility': "Shenzhen Second People's Hospital", 'geoPoint': {'lat': 22.54554, 'lon': 114.0683}}, {'zip': '530007', 'city': 'Nanning', 'state': 'Guangxi', 'country': 'China', 'contacts': [{'name': 'CunDong Mi, Master', 'role': 'CONTACT', 'email': 'Md-392@126.com', 'phone': '15807801372'}], 'facility': 'The Second Affiliated Hospital of Guangxi Medical University', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'zip': '550004', 'city': 'Guiyang', 'state': 'Guizhou', 'country': 'China', 'contacts': [{'name': 'Jiashun Zeng, Doctor', 'role': 'CONTACT', 'email': 'zengjiashun@sina.com', 'phone': '13984846802'}], 'facility': 'The Affiliated Hospital of Guizhou Medical University', 'geoPoint': {'lat': 26.58333, 'lon': 106.71667}}, {'zip': '071000', 'city': 'Baoding', 'state': 'Hebei', 'country': 'China', 'contacts': [{'name': 'Junqiao Li, Bachelor', 'role': 'CONTACT', 'email': 'bdyzxljq@163.com', 'phone': '18617789105'}], 'facility': 'Bao Ding NO.1 Central', 'geoPoint': {'lat': 38.87288, 'lon': 115.46246}}, {'zip': '061000', 'city': 'Cangzhou', 'state': 'Hebei', 'country': 'China', 'contacts': [{'name': 'Weiwei Lu, Master', 'role': 'CONTACT', 'email': '11070307@qq.com', 'phone': '18031783702'}], 'facility': 'Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine', 'geoPoint': {'lat': 38.31124, 'lon': 116.85334}}, {'zip': '475000', 'city': 'Kaifeng', 'state': 'Henan', 'country': 'China', 'contacts': [{'name': 'Zhexin Wang, Bachelor', 'role': 'CONTACT', 'email': 'kfwzx1020@163.com', 'phone': '13949401020'}], 'facility': "Kaifeng People's Hospital", 'geoPoint': {'lat': 34.7986, 'lon': 114.30742}}, {'zip': '471002', 'city': 'Luoyang', 'state': 'Henan', 'country': 'China', 'contacts': [{'name': 'Hongli Hou, Master', 'role': 'CONTACT', 'email': 'beckhansome@163.com', 'phone': '13838861918'}], 'facility': 'Luoyang Orthopedic-Traumatological Hospital Of Henan Province(Henan Provincial Orthopedic Hospital)', 'geoPoint': {'lat': 34.67345, 'lon': 112.43684}}, {'zip': '471003', 'city': 'Luoyang', 'state': 'Henan', 'country': 'China', 'contacts': [{'name': 'Xiaofei Shi, Master', 'role': 'CONTACT', 'email': 'sxf64817332@163.com', 'phone': '13663884080'}], 'facility': 'The First Affiliated Hospital of Henan University of science and Technology', 'geoPoint': {'lat': 34.67345, 'lon': 112.43684}}, {'zip': '450003', 'city': 'Zhengzhou', 'state': 'Henan', 'country': 'China', 'contacts': [{'name': 'Hongtao Guo, Doctor', 'role': 'CONTACT', 'email': 'guoht2009@126.com', 'phone': '187399916938'}], 'facility': 'The First Affiliated Hospital of Henan University of CM', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '410008', 'city': 'Changsha', 'state': 'Hunan', 'country': 'China', 'contacts': [{'name': 'Juan Su, Doctor', 'role': 'CONTACT', 'email': '3694944834@qq.com', 'phone': '15116408921'}], 'facility': 'Xiangya Hospital of Central South University', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'zip': '422000', 'city': 'Shaoyang', 'state': 'Hunan', 'country': 'China', 'contacts': [{'name': 'Shiliang Hu, Bachelor', 'role': 'CONTACT', 'email': '153348793@qq.com', 'phone': '15873929871'}], 'facility': 'The Central Hospital of Shaoyang', 'geoPoint': {'lat': 27.23818, 'lon': 111.46214}}, {'zip': '412000', 'city': 'Zhuzhou', 'state': 'Hunan', 'country': 'China', 'contacts': [{'name': 'Zhenhua Wen, Master', 'role': 'CONTACT', 'email': '151728544@qq.com', 'phone': '13387411981'}], 'facility': 'Zhuzhou Central Hospital', 'geoPoint': {'lat': 27.83333, 'lon': 113.15}}, {'zip': '210001', 'city': 'Nanjing', 'state': 'Jiangsu', 'country': 'China', 'contacts': [{'name': 'WenFeng TAN, Postdoctoral', 'role': 'CONTACT', 'email': 'Tanwenfeng@gmail.com', 'phone': '13770769608'}], 'facility': 'Jiangsu Peopince Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '210008', 'city': 'Nanjing', 'state': 'Jiangsu', 'country': 'China', 'contacts': [{'name': 'Lingyun Sun, Doctor', 'role': 'CONTACT', 'email': 'lingyunsun2012@163.com', 'phone': '13705186409'}], 'facility': 'Nanjing Drum Tower Hospital', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'zip': '215004', 'city': 'Suzhou', 'state': 'Jiangsu', 'country': 'China', 'contacts': [{'name': 'Zhichun Liu, Doctor', 'role': 'CONTACT', 'email': 'lzchun5190@sina.com', 'phone': '13771994276'}], 'facility': 'The Second Affiliated Hospital of Soochow University', 'geoPoint': {'lat': 31.30408, 'lon': 120.59538}}, {'zip': '224000', 'city': 'Yancheng', 'state': 'Jiangsu', 'country': 'China', 'contacts': [{'name': 'Xiangdong Ren, Bachelor', 'role': 'CONTACT', 'email': 'rxd_2025@qq.com', 'phone': '13770070889'}], 'facility': "Yancheng No.1 People's Hospital", 'geoPoint': {'lat': 33.3575, 'lon': 120.1573}}, {'zip': '330006', 'city': 'Nanchang', 'state': 'Jiangxi', 'country': 'China', 'contacts': [{'name': 'Rui Wu, Doctor', 'role': 'CONTACT', 'email': '13970997559@139.com', 'phone': '13970997559'}], 'facility': 'The First Affiliated Hospital of Nanchang University', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '330006', 'city': 'Nanchang', 'state': 'Jiangxi', 'country': 'China', 'contacts': [{'name': 'Xinwang Duan, Doctor', 'role': 'CONTACT', 'email': '13970085678@163.com', 'phone': '13970085678'}], 'facility': 'The Second Affiliated Hospital of Nanchang University', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'zip': '337000', 'city': 'Pingxiang', 'state': 'Jiangxi', 'country': 'China', 'contacts': [{'name': 'Senhua Dai, Master', 'role': 'CONTACT', 'email': '15979222982@163.com', 'phone': '159 7922 2982'}], 'facility': "Pingxiang People's Hospital", 'geoPoint': {'lat': 27.61672, 'lon': 113.85353}}, {'zip': '130000', 'city': 'Changchun', 'state': 'Jilin', 'country': 'China', 'facility': "Jilin Provincial People's Hospital", 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '130021', 'city': 'Changchun', 'state': 'Jilin', 'country': 'China', 'contacts': [{'name': 'Zhenyv Jiang, Doctor', 'role': 'CONTACT', 'email': 'jzyd0197@163.com', 'phone': '15843079623'}], 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '116000', 'city': 'Dalian', 'state': 'Liaoning', 'country': 'China', 'contacts': [{'name': 'Xiaodan Kong, Doctor', 'role': 'CONTACT', 'email': 'xiaodankong2008@sina.com', 'phone': '17709876336'}], 'facility': 'The second hospital of dalian medical university', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}}, {'zip': '110001', 'city': 'Shenyang', 'state': 'Liaoning', 'country': 'China', 'contacts': [{'name': 'Hui Shen, Doctor', 'role': 'CONTACT', 'email': 'shenhuicam@souhu.com', 'phone': '13898897439'}], 'facility': 'The First Hospital of China Medical University', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'zip': '250021', 'city': 'Jinan', 'state': 'Shandong', 'country': 'China', 'contacts': [{'name': 'Hongsheng Sun, Master', 'role': 'CONTACT', 'email': '13869192509@126.com', 'phone': '15168888385'}], 'facility': 'Shandong Provincial Hospital', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '261000', 'city': 'Weifang', 'state': 'Shandong', 'country': 'China', 'contacts': [{'name': 'Jingjing Ma, Master', 'role': 'CONTACT', 'email': 'wfmjj001@163.com', 'phone': '13626469450'}], 'facility': "Weifang People'S Hospital", 'geoPoint': {'lat': 36.71, 'lon': 119.10194}}, {'zip': '201821', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'contacts': [{'name': 'Xinying Liu, Doctor', 'role': 'CONTACT', 'email': 'liuxinying@tongji.edu.cn', 'phone': '18917684056'}], 'facility': "Shanghai Tenth People's Hospital", 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '041099', 'city': 'Linfen', 'state': 'Shanxi', 'country': 'China', 'facility': 'Linfen Central Hospital', 'geoPoint': {'lat': 36.08889, 'lon': 111.51889}}, {'zip': '618199', 'city': 'Deyang', 'state': 'Sichuan', 'country': 'China', 'contacts': [{'name': 'Lin Feng, Bachelor', 'role': 'CONTACT', 'email': '18090757371@163.com', 'phone': '13708103308'}], 'facility': "Deyang People's Hospital", 'geoPoint': {'lat': 31.13019, 'lon': 104.38198}}, {'zip': '646000', 'city': 'Luzhou', 'state': 'Sichuan', 'country': 'China', 'facility': 'Affiliated Hospital of Southwest Medical University', 'geoPoint': {'lat': 28.8903, 'lon': 105.42575}}, {'zip': '637100', 'city': 'Nanchong', 'state': 'Sichuan', 'country': 'China', 'facility': 'Hospital of North Sichuan Medical College', 'geoPoint': {'lat': 30.79508, 'lon': 106.08473}}, {'zip': '300120', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'country': 'China', 'contacts': [{'name': 'Litao Zhang, Doctor', 'role': 'CONTACT', 'email': 'ZhanglitaoYG@163.com', 'phone': '18602228122'}], 'facility': 'Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '300120', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'country': 'China', 'contacts': [{'name': 'Weifeng Yao, Doctor', 'role': 'CONTACT', 'email': 'weifeng96033@163.com', 'phone': '15620250048'}], 'facility': 'Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '830001', 'city': 'Ürümqi', 'state': 'Xinjiang', 'country': 'China', 'contacts': [{'name': 'Lijun Wu, Bachelor', 'role': 'CONTACT', 'email': 'wwlj330@126.com', 'phone': '13999265917'}], 'facility': "Xinjiang Uygur Autonomous Region People's Hospital", 'geoPoint': {'lat': 43.80096, 'lon': 87.60046}}, {'zip': '310000', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'contacts': [{'name': 'Yongmei Han, Master', 'role': 'CONTACT', 'email': 'yujiangnan58@163.com', 'phone': '15057155500'}], 'facility': 'Sir Run Run Shaw Hospital, Zhejiang University School of Medicine', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '310003', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'contacts': [{'name': 'Jin Lin, Doctor', 'role': 'CONTACT', 'email': 'linjinzju@163.com', 'phone': '13906539996'}], 'facility': 'The First Affiliated Hospital, Zhejiang University School of Medicine', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '315010', 'city': 'Ningbo', 'state': 'Zhejiang', 'country': 'China', 'contacts': [{'name': 'Jin Zhang, Master', 'role': 'CONTACT', 'email': '751860714@qq.com', 'phone': '13486089482'}], 'facility': 'Ningbo Medical Center Li HuiLi Hospital', 'geoPoint': {'lat': 29.87819, 'lon': 121.54945}}], 'centralContacts': [{'name': 'Xiaofeng Zeng, Doctor', 'role': 'CONTACT', 'email': 'xiaofeng.zeng@cstar.org.cn', 'phone': '13501069845'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}